Abstract: The present invention relates to a compound having the following formula (1) wherein: R and R? are, independently from each other, H or (C1-C6)alkyl groups, or form together with the carbon atoms carrying them a (C6-C10)aryl group; R2 is selected from the group consisting of: H, (C1-C6)alkyl group, halo(C1-C6)alkyl group, aryl, and heteroaryl; A1 is a linker; R? is either a group (A-1) or a group (A-2) for use in the treatment of a brain disorder involving modified 5-HT7R-mediated signaling, especially for use in the treatment of pain or inflammation or in the treatment of multiple sclerosis, or for use to induce hypothermia.

Abstract: The present invention relates to a compound of formula (I) wherein R1 represents a (C1-C6)alkyl group, a spiro(C5-C11)bicyclic ring, a fused phenyl group, a substituted phenyl group, a R?-L- group, wherein L is either a single bond or a (C1-C3)alkanediyl group, and R? represents a (C3-C8)cycloalkyl group, abridged (C6-C10)cycloalkyl group, a (C3-C8)heterocycloalkyl group, or a (C3-C8)heteroaryl group, or a R?-L- group wherein L is a (C1-C3)alkanediyl group, and R? is an optionally substituted phenyl group, and wherein R2 represents a hydrogen atom or a (C1-C3)alkyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates.